Neel Gandhi
Hematology & Oncology · Lawrenceville, NJNPI 1033385877
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 80.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $4,571 and has fallen 94.0% since, to $272 in 2023.
Across 51 payments — averaging $102.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$125
- Foundation Medicine, Inc.$105
- Sanofi-aventis U.S. LLC$100
- Novartis$74
- Amgen$70
- plus $522 from 19 others
Across 218 payments — averaging $3222.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$423K
- Biontech SE$185K
- Merck Healthcare Kgaa$58K
- AbbVie$35K
- Nuvation Bio Inc.$1K
What the payments were for
- Consulting fees$2,80054%
- Travel & lodging$86517%
- Food & beverage$1,43327%
- Education$1122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $4,215 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $125 |
| Foundation Medicine, Inc. | 2 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Novartis | 4 | $74 |
| Amgen | 4 | $70 |
| Veran Medical Technologies, Inc. | 1 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Johnson & Johnson(2 entities) | 3 | $52 |
| Octapharma USA, Inc. | 1 | $38 |
| Sanofi | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Incyte Corporation | 2 | $30 |
| Lilly USA, LLC | 2 | $29 |
| Bristol Myers Squibb | 1 | $21 |
| Beigene USA, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Advanced Accelerator Applications | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,211 in reported general payments places this provider in the 60th percentile of 362 hematology & oncology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $9,224 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lawrenceville
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
- Anthony BottiLivingston$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.